Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.54, compared with -$0.5 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.71.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 5 analysts of -$1.24 (+26.0%) for the fiscal year ending Dec 2026, a slowdown from the +70.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.54-68.8% QoQ
- Last fiscal yearDec 2025
- -$1.67+70.2% YoY
- LTMMar 2026
- -$1.71+45.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -7.6% | +9.4% | +17.0 pp |
| 1 year | +70.2% | +26.0% | -44.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.67) USD
- Year-over-year change
- +70.2%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.67) | +70.2% |
| FY2024 | 2024-12-31 | (5.60) | -337.5% |
| FY2023 | 2023-12-31 | (1.28) | -6.7% |
| FY2022 | 2022-12-31 | (1.20) | +86.0% |
| FY2021 | 2021-12-31 | (8.60) | — |
EPS (Diluted) vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +45.1% is the 6th highest of 10, against a peer median of +55.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.14 USD | +147.7% | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | -CA$0.29 CAD | +81.9% | — |
| LTM Mar 2026 | -$0.89 USD | +75.0% | — | |
| LTM Mar 2026 | -$1.11 USD | +55.8% | — | |
| LTM Mar 2026 | -$1.49 USD | -313.9% | — | |
| LTM Mar 2026 | -$1.71 USD | +45.1% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | -$1.77 USD | +84.8% | — |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$2 USD | +9.9% | — |
| LTM Mar 2026 | -$2.27 USD | +19.2% | — | |
| LTM Mar 2026 | -$5.98 USD | +39.0% | — | |
| Peer median (excluding UNCY) | — | +55.8% | — | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 951K | 675K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 572K |
| Gross Profit | 0 | 951K | 675K | 0 | (572K) |
| Gross Margin | — | 100.0% | 100.0% | — | — |
| Research & Development | 6.08M | 12.44M | 12.9M | 20.01M | 9.12M |
| Selling, General & Admin | 2.9M | 6.57M | 8.55M | 12.1M | 20.4M |
| Operating Expenses | 8.98M | 19M | 21.45M | 32.12M | 28.95M |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| EBITDA | (9.38M) | (17.89M) | (30.18M) | (36.23M) | (25.91M) |
| EBITDA Margin | — | -1881.3% | -4470.8% | — | — |
| Operating Income | (8.98M) | (18.05M) | (20.77M) | (32.12M) | (29.52M) |
| Operating Margin | — | -1898.2% | -3077.6% | — | — |
| Interest Income | 0 | 0 | 615K | 1.26M | 1.01M |
| Interest Expense | 628K | 6K | 82K | 71K | 71K |
| Other Income / Expenses | (1.04M) | (6K) | (9.77M) | (4.61M) | 2.96M |
| Income Before Tax | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Pre-Tax Margin | — | -1898.8% | -4525.0% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Net Margin | — | -1898.8% | -4525.0% | — | — |
| EPS (Basic) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| EPS (Diluted) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| Weighted Avg Shares | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
| Weighted Avg Shares (Diluted) | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.